Background Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgita
Background Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgita
背景：病例报告和超声心动图研究提示，用于治疗帕金森病和不宁腿综合征的药物—麦角洐生物，多巴胺受体激动剂培高利特和卡麦角林，可能增加发生心脏瓣膜返流的风险。